FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility
Express News | Amex Halt Add Info Lst 8.340000
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Enveric Biosciences Announces Pharmacology and Safety Data For EB-003, Says 'In Vitro Pharmacology Studies Confirmed EB-003's Ability to Target Desired Serotonergic Receptors'
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Clearmind Medicine Shares Are Trading Higher After the Company Announced It Has Received Institutional Review Board Approval From One of Its Clinical Sites in the U.S. for Part A of Its Phase I/IIa Clinical Trial in the United States for Treating...
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Incannex Healthcare Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in FY24 EPS Results.
Enveric Biosciences Presents Data Highlighting Development Of EB-003 At European Behavioral Pharmacology Society Biennial Workshop Held In Banff, Alberta, Canada On September 26, 2024.
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
ADVISORSHARES PSYCHEDELICS ETF To Go Ex-Dividend On September 23rd, 2024 With 0.1087 USD Dividend Per Share
September 20th (Eastern Time) - $ADVISORSHARES PSYCHEDELICS ETF(PSIL.US)$ is trading ex-dividend on September 23rd, 2024.Shareholders of record on September 23rd, 2024 will receive 0.1087 USD
Relmada Jumps as Jefferies Upgrades on a Potential Turnaround Story
Relmada Therapeutics Analyst Ratings
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
JMP Securities Reiterates Market Outperform on GH Research, Maintains $39 Price Target